Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;44(6):1342-1350.
doi: 10.1007/s11096-022-01464-x. Epub 2022 Sep 28.

A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country

Nancy Zaghloul  1   2 , Ahmed Awaisu  2 , Ahmed Mahfouz  1 , Sumaya Alyafei  1 , Hazem Elewa  3   4
Affiliations

A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country

Nancy Zaghloul et al. Int J Clin Pharm. 2022 Dec.

Abstract

Background: Sodium glucose co-transporter 2 inhibitors (SGLT2is) are a novel class of oral antidiabetic drugs. To date, there are no pharmacoepidemiologic studies investigating the pattern of use of SGLT2is compared to other oral antidiabetic drugs in the Middle East, including Qatar.

Aim: This study aimed to explore the trends in the use of SGLT2is compared to other oral antidiabetic drugs in Qatar from 2016 to 2020.

Method: This is a descriptive, retrospective cross-sectional study where information on all oral antidiabetic drugs dispensed as in- or out-patient prescriptions from 2016 to 2020 in Hamad Medical Corporation hospitals, Qatar were collected. Outcomes included the number and relative frequency of quarterly prescriptions of different oral antidiabetic drug classes [biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, meglitinides, α-glucosidase inhibitors, and SGLT2is] prescribed from 2016 to 2020.

Results: SGLT2is prescriptions increased from 1045 (2.13%) in 2017 to 8375 (12.39%) in 2020, while sulfonylureas prescriptions declined from 10,436 (21.25%) to 9158 (13.55%) during the same period. Metformin use decreased from 23,926 (48.71%) in 2017 to 30,886 (45.70%) in 2020. The proportions of thiazolidinediones, meglitinides, α-glucosidase inhibitors prescriptions remained stable over the years. Among SGLT2is, empagliflozin prescriptions showed an increase from 537 (10.65%) to 2881 (34.40%) compared to dapagliflozin, which decreased by the end of 2018 from 4505 (89.35%) to 5494 (65.6%).

Conclusion: SGLT2is have largely replaced sulfonylureas in Qatar. The increasing trend in their use over the years is similar to that reported in other countries. The trend among SGLT2is suggests greater preference for empagliflozin over dapagliflozin.

Keywords: Diabetes mellitus; Hypoglycemic agents; Qatar; Sodium-glucose transporter 2 inhibitors; Trends; Type 2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Trends in the use of oral antidiabetic drugs from 2016 to 2020. ADDs, antidiabetic drugs; BGs, biguanides (metformin); SUs, sulfonylureas; DPP4is, dipeptidyl peptidase 4 inhibitors; TZDs, thiazolidinediones; MEGs, meglitinides; AGIs, α-glucosidase inhibitors; SGLT2is, sodium-glucose co-transporter 2 inhibitors
Fig. 2
Fig. 2
Trends in the use of sodium–glucose co-transporter 2 inhibitors from 2018 to 2020
Fig. 3
Fig. 3
Trends of most frequently prescribed oral antidiabetic drugs combinations from 2016 to 2020
Fig. 4
Fig. 4
Trends of most frequently prescribed oral antidiabetic drugs combinations of a monotherapy, b dual therapy, and c triple therapy from 2016 to 2020. BGs, biguanides (metformin); SUs, sulfonylureas; DPP4is, dipeptidyl peptidase 4 inhibitors; TZDs, thiazolidinediones; MEGs, meglitinides; SGLT2is, sodium-glucose co-transporter 2 inhibitors
See this image and copyright information in PMC

References

    1. American Diabetes Association 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S111–S124. doi: 10.2337/dc21-S009. - DOI - PubMed
    1. Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 Update. Can J Diabetes. 2020;44:575–591. doi: 10.1016/j.jcjd.2020.08.001. - DOI - PubMed
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract. 2019;25:69–100. doi: 10.4158/CS-2018-0535. - DOI - PubMed
    1. Buse JB, Wexler DJ, Tsapas A, et al. Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD) Diabetes Care. 2019;43:487–93. doi: 10.2337/dci19-0066. - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline 2015. https://www.nice.org.uk/guidance/ng28. Accessed 09.07.2021. - PubMed